Interactive Obesity Treatment Approach (iOTA) for Obesity Prevention in Serious Mental Illness

NCT ID: NCT03695289

Last Updated: 2020-07-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-07-05

Study Completion Date

2020-06-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The proposed project aims to pilot and adapt a scalable and sustainable interactive obesity treatment approach (iOTA) program for adults with serious mental illness (SMI). The project consists of 2 arms: the iOTA SMI arm and the Health Education Control Group arm. The investigators hypothesize that participants in the iOTA intervention group will show favorable change in BMI compared to participants in the Health Education Control group, and participants in the iOTA intervention group will show favorable change in self efficacy with respect to healthy eating and activity compared to those in the Health Education Control group.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Obesity is highly prevalent among chronically-treated individuals with severe mental illness (SMI), exceeding general population rates and contributing to type 2 diabetes, cardiovascular disease (CVD) and premature mortality. Behavioral interventions to reverse obesity in chronic SMI have shown limited effectiveness. There are currently no FDA-approved pharmacotherapies for obesity in SMI, and off-label pharmacotherapies used for weight loss are associated with limited effectiveness or serious adverse event risks. Prior obesity interventions for SMI have often been designed for delivery by existing community mental health center (CMHC) caseworkers/staff. However, mental health workers commonly perceive themselves as overworked and/or career-specialized for psychological rather than medical care, creating barriers to sustainable provider engagement.

Using a design-for-dissemination approach, initial development of the intervention under study incorporated trained health coaches using scalable, inexpensive technology to increase intervention engagement, effectiveness, sustainable reach and cost-effectiveness. Derived from the effective lifestyle intervention used in the Diabetes Prevention Program, the initial parent Interactive Obesity Treatment Approach (iOTA) intervention targets diet, activity and medication adherence, incorporating electronic (e.g., web-based) and interpersonal health coach support. That parent iOTA produces weight loss at 24 months in low-income, racially diverse, community health center populations with obesity, and became a platform for further adaptations of iOTA interventions for other populations and environments, targeting low-income populations with limited web and computer access. Using a formal evaluation process and implementation science framework, the parent iOTA intervention was subsequently adapted to low-income workplace environments, (the Working for You or WfY study, RO1 DK103760; PI: Evanoff) amplifying face-to-face health coach and peer interactions with interactive, semi-automated SMS text messaging, a highly utilized technology among low-income populations.

The investigators further adapted the WfY iOTA for use in adults with chronic SMI using Innovation Corps (I-Corps) methods. Created by the National Science Foundation (NSF) and supported by NIH (PA-18-314), I-Corps uses the Lean Launchpad approach developed by serial entrepreneurs at Stanford for translating academic innovation into practice. The emphasis is on immediate and iterative elicitation of stakeholder feedback via focus groups or short interviews. Using stakeholder input, investigators revise assumptions and hypotheses, testing redesigned offerings and making adjustments to ideas that are not working. In conducting our interviews, we identified "customer" specific (e.g. client, clinician and administrator) barriers to implementation of an un-adapted iOTA in mental health treatment centers. Themes that consistently emerged were concern about limited human resources and added work burden not directly related to the mental health of clients, while clients expressed a desire for more in-person and telephonic coaching time, in addition to text messaging.

Now, the investigators propose to use an overarching treatment adaptation framework18 to further refine our treatment to be more readily implementable for individuals with chronic SMI treated in the CMHC setting. Reproducible adaptation of effective interventions to new target populations and settings requires a formal evaluation process and an implementation science framework. Our overarching aim for this application is to pilot and iteratively adapt a scalable and sustainable iOTA for adults with SMI, planning for future effectiveness testing in a well-powered randomized controlled trial (RCT), and eventual large scale dissemination and implementation.

Aim 1: Conduct a randomized pilot and feasibility study of iOTA-SMI in a diverse sample of adults with chronic SMI, comparing iOTA-SMI to a health education control condition. iOTA-SMI will be piloted in a representative sample of 40 adults ages 18-60 with SMI, randomizing participants 2:1 to 16 weeks of iOTA-SMI versus monthly health education. We hypothesize favorable differences in BMI for iOTA-SMI compared to control. Secondary analyses will assess iOTA effects on health self-efficacy, exploring the relationship between effects on Body Mass Index (BMI) and the target mechanism.

Aim 2: Evaluate feasibility and acceptability of iOTA implementation, making iterative adaptations based on data collected during the pilot. Feasibility, engagement and implementation challenges will be characterized, measured by i) enrollment and retention, ii) obesity intervention acceptability, iii) text response rates, iv) visit adherence v) client expectations, vi) fidelity and vii) CMHC staff-rated acceptability, appropriateness and burden.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity Mentally Ill Persons

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

iOTA-SMI

Participants randomized to iOTA-SMI arm will participate in a 16 week interactive obesity treatment approach (iOTA) program approach.

Group Type EXPERIMENTAL

iOTA SMI

Intervention Type BEHAVIORAL

Participants randomized to the iOTA SMI arm will undergo an assessment of individual behavior risks, will participate in collaborative goal-setting with a health coach, and will use an interactive text system that will provide ongoing support and self-monitoring of behavior change goals.

Health Education Control

Participants randomized to the Health Education Control arm will receive monthly in-person health coaching visits for 16 weeks.

Group Type ACTIVE_COMPARATOR

Health Education Control

Intervention Type BEHAVIORAL

Participants randomized to the Health Education Control arm will receive monthly counseling on energy balance, physical activity and nutrition.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

iOTA SMI

Participants randomized to the iOTA SMI arm will undergo an assessment of individual behavior risks, will participate in collaborative goal-setting with a health coach, and will use an interactive text system that will provide ongoing support and self-monitoring of behavior change goals.

Intervention Type BEHAVIORAL

Health Education Control

Participants randomized to the Health Education Control arm will receive monthly counseling on energy balance, physical activity and nutrition.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* aged 18-60 years
* BMI ≥ 28
* have a diagnosis of a severe and persistent mental illness
* psychiatric symptoms present for at least 6 months prior to screening
* at least 6 months of lifetime antipsychotic exposure prior to screening
* not taking weight loss medications or participating in another behavioral weight loss intervention
* enrolled in case management services
* able to provide written informed consent

Exclusion Criteria

* acute suicidality at time of screening
* active substance use disorder diagnosis
* unable or unwilling to provide written informed consent
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Washington University School of Medicine

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ginger E Nicol, MD

Role: PRINCIPAL_INVESTIGATOR

Washington University School of Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Washington University School of Medicine

St Louis, Missouri, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Correll CU, Druss BG, Lombardo I, O'Gorman C, Harnett JP, Sanders KN, Alvir JM, Cuffel BJ. Findings of a U.S. national cardiometabolic screening program among 10,084 psychiatric outpatients. Psychiatr Serv. 2010 Sep;61(9):892-8. doi: 10.1176/ps.2010.61.9.892.

Reference Type BACKGROUND
PMID: 20810587 (View on PubMed)

Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis. 2006 Apr;3(2):A42. Epub 2006 Mar 15.

Reference Type BACKGROUND
PMID: 16539783 (View on PubMed)

Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis. Schizophr Bull. 2013 Mar;39(2):306-18. doi: 10.1093/schbul/sbr148. Epub 2011 Dec 29.

Reference Type BACKGROUND
PMID: 22207632 (View on PubMed)

Newcomer JW, Hennekens CH. Severe mental illness and risk of cardiovascular disease. JAMA. 2007 Oct 17;298(15):1794-6. doi: 10.1001/jama.298.15.1794. No abstract available.

Reference Type BACKGROUND
PMID: 17940236 (View on PubMed)

Daumit GL, Dickerson FB, Wang NY, Dalcin A, Jerome GJ, Anderson CA, Young DR, Frick KD, Yu A, Gennusa JV 3rd, Oefinger M, Crum RM, Charleston J, Casagrande SS, Guallar E, Goldberg RW, Campbell LM, Appel LJ. A behavioral weight-loss intervention in persons with serious mental illness. N Engl J Med. 2013 Apr 25;368(17):1594-602. doi: 10.1056/NEJMoa1214530. Epub 2013 Mar 21.

Reference Type BACKGROUND
PMID: 23517118 (View on PubMed)

Robinson DG, Schooler NR, Correll CU, John M, Kurian BT, Marcy P, Miller AL, Pipes R, Trivedi MH, Kane JM. Psychopharmacological Treatment in the RAISE-ETP Study: Outcomes of a Manual and Computer Decision Support System Based Intervention. Am J Psychiatry. 2018 Feb 1;175(2):169-179. doi: 10.1176/appi.ajp.2017.16080919. Epub 2017 Sep 15.

Reference Type BACKGROUND
PMID: 28945118 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

201806118

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.